On October 20, a long-anticipated event will take place in Brazil: the patent on semaglutide-based weight-loss pens, sold under the names Ozempic and Wegovy, will expire. While the effects on medication prices won't be immediate, the introduction of generics is anticipated to significantly increase the accessibility and use of these weight-loss pens in the coming years. This raises important considerations for various sectors, specifically the food industry and restaurants, which may have to adjust their offerings in response to changing consumer appetites.

As more generics hit the market and competition increases, there could be a notable decline in the demand for larger food portions and traditional restaurant offerings. The article suggests that while the current effects may be largely felt among wealthier individuals, the ramifications for the food industry at large could be significant and long-lasting. This shift could lead to what has been characterized as a decrease in appetite, consequently influencing how restaurants operate and what they offer.

While it is unlikely that restaurants will face a widespread closure due to this trend, they will nonetheless need to adapt to the changes in consumer behavior and preferences. The adjustments they make will likely redefine dining experiences, menu options, and serving sizes, as the market responds to the increasing popularity of weight-loss treatments. The article posits that these changes are only the beginning, hinting at a transformative period for the food and restaurant sectors in Brazil as the accessibility of weight-loss drugs increases across demographics.